Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris

Journal of Cutaneous Medicine and Surgery

Volumn 10, Issue 5, 2006, Pages 222-227

  Mittmann, Nicole ^a   Chan, Brian ^b   Knowles, Sandra ^b   Mydlarski, P Régine ^b   Cosentino, Lidia ^b   Shear, Neil ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; DRUG COMBINATION; MIDDLE AGED; PEMPHIGUS; RETROSPECTIVE STUDY;

DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34047190477     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2006.00053     Document Type: Article

References (20)

1. Stanley JR. Pemphigus. In: Freedberg IM, Eisen AZ, Wolff K, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. Toronto: McGraw-Hill; 1999. p. 654-65.
2. Pisanti S, Sharav Y, Kaufman E, Posner LN. Pemphigus vulgaris: incidence in Jews of different ethnic groups, according to age, sex, and initial lesion. Oral Surg Oral Med Oral Pathol 1974;38:382-7.
3. Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol 1982;62:491-6.
4. Simon DG, Krutchkoff D, Kaslow RA, Zarbo R. Pemphigus in Hartford County, Connecticut, from 1972 to 1977. Arch Dermatol 1980;116:1035-7.
5. Harman KE, Albert S, Black MM, British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-37.
6. Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch Dermatol 1984;120:44-7.
7. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens. A 5-year study. Int J Dermatol 1990;29:363-7.
8. Lapidoth M, David M, Ben-Amitai D, et al. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994;30(5 Pt 1):752-7.
9. Bystryn JC. Adjuvant therapy of pemphigus. Arch Dermatol 1984;120:941-51.
10. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000;136:868-72.
11. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42:422-7.
12. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.
13. Lin AN, Paget SA. Principles of corticosteroid therapy. 1st ed. New York: Oxford University Press; 2002.
14. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001;45:679-90.
15. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002;138:1158-62.
16. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005;142:1-11.
17. Mimouni D, Blank M, Ashkenazi L, et al. Protective effect of intravenous immunoglobulin (IVIG) in an experimental model of pemphigus vulgaris. Clin Exp Immunol 2005;142:426-32.
18. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.
19. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris. J Am Acad Dermatol 2000;43:1049-57.
20. Baum S, Scope A, Barzilai A, et al. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006;20:548-52.